Pembrolizumab vs. chemotherapy in the first-line setting of PD-L1 ≥ 50% metastatic non-small cell lung cancer: a real-world cost-effectiveness analysis
Liu B, Parmar A, Luo J, Dai WF, Chan KKW. Eur J Health Econ. 2025; Oct 8 [Epub ahead of print].
Publications
Impact of direct oral anticoagulant uptake on hospitalizations for stroke/transient ischemic attack, intracranial hemorrhage, and gastrointestinal bleeding in individuals with atrial fibrillation: a population-based study
Antoniou T, McCormack D, Wang T, Tadrous M, Gomes T. Fundam Clin Pharmacol. 2025; 39(6):e70051.
Palliative care with tracheostomy or gastrostomy tube use and end-of-life quality and costs among patients with head and neck cancer
Fu R, Sutradhar R, Li Q, Villemure-Poliquin N, Chan KKW, Karam I, Hallet J, Eskander A. JAMA Otolaryngol Head Neck Surg. 2025; Sep 25 [Epub ahead of print].
Association of frailty with healthcare utilization and days alive at home in patients with gynecologic cancers: a population-based study
Nguyen JM, Zigras T, Gayowsky A, Marcucci M, Costa A, Vicus D, Nica A, Hogen L, Perez R. Am J Obstet Gynecol. 2025; S0002-9378(25)00488-0. Epub 2025 Jul 17.
Patients with head and neck cancer and high health care costs: a population-based study
Villemure-Poliquin N, Fu R, Li Q, Ayoo K, Chan KKW, Karam I, Wright FC, Coburn NG, Hallet J, Eskander A. JAMA Otolaryngol Head Neck Surg. 2025; e251976. Epub 2025 Jul 17.
A longitudinal analysis of the economic cost of all phases of TB care in a low incidence setting
Ramsay LC, Brode SK, Rea E, Barrett K, Hernandez A, Iragorri N, Liu K, Macdonald L, Sander B. IJTLD Open. 2025; 2(7):404-411.
Healthcare resource utilisation and costs associated with hypertension in children and adolescents: a population-based cohort study
Hussain J, Ahmed R, Robinson CH, Jeyakumar N, Smith G, Brady TM, Dart AB, Dionne J, Karam S, McKay A, Parekh RS, Sinha MD, South AM, Vincent C, Chanchlani R. Lancet Reg Health Am. 2025; 48:101157.
Is Ontario ready for the health costs associated with dementia?
Bronskill SE, Maclagan LC, Mondor L, Fu L, Guan J, Sewell IJ, Iaboni A, Swartz RH, Maxwell CJ, de Oliveira C. Healthc Q. 2025; 28(1):7-11.
Trends in the cost and utilization of publicly reimbursed cancer medications dispensed as take-home treatments from 2017-2021
Garg R, Dumont T, McCormack D, Tadrous M, Campbell T, Chan K, Gomes T. Curr Oncol. 2025; 32(4):237.
Trends in the cost and utilization of publicly dispensed respiratory inhalers in Ontario, Canada: a repeated cross-sectional study
Garg R, Wang T, Tadrous M, Antoniou T, Gomes T. Pharmacoepidemiol Drug Saf. 2025; 34(4):e70125.